Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

This activity is supported by an educational grant from AstraZeneca.

Literature Highlights

Publications

Clear Search

Showing 1 result for “Deucravacitinib” published 2022.

December 2022
Publication thumbnail: Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial View Slides

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial

, , , , , , , , , , , ,

Arthritis Rheumatol. 2022. Epub ahead of print doi: 10.1002/art.42391

Phase II trial results of deucravacitinib support the potential benefits of TYK2 inhibition in SLE.

more…

Keywords: